The Asia Pacific Endometriosis Market would witness market growth of 12.5% CAGR during the forecast period (2022-2028).
Treatments exist that can lessen the disease's progression and improve symptoms. Treatments include painkillers like hormone supplements, ibuprofen, and paracetamol, and contraceptives, surgery to remove endometriosis tissue patches by cutting them out or by lasering (vaporizing) them, and an operation to remove all or some of the damaged organs.
The inability to conceive is one of the main effects of endometriosis. The patient might never be able to become pregnant (infertility). Having endometriosis surgically removed can increase a woman's chances of becoming pregnant. However, there is no assurance that they will be able to conceive after treatment. Endometriosis surgery could result in further complications. For instance, organ damage, hemorrhage, or infections. If surgery is advised, discuss the potential risks with the surgeon.
Due to a lack of menstrual awareness, restricted access to sanitary products, and a hostile school environment, girls may find it challenging to attend class. India's government and non-governmental organizations have created programs to minimize the difficulty of schoolgirls' menstruation (NGOs). This sought to identify barriers to menstruation management in schools and facilitators in three Indian states. The Indian government has established several programs to improve menstrual hygiene management (MHM) in schools, with assistance from a number of organizations, with the goal of enhancing knowledge about feminine hygiene and related diseases. It also plays a significant role in raising awareness among women regarding menstrual hygiene, well-being, and educational achievements. Women in this region experience a variety of menstrual issues, which inspires them to use femtech apps for efficient care. This will spur market expansion in the Asia Pacific region.
The China market dominated the Asia Pacific Endometriosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $177.3 million by 2028. The Japan market is estimated to grow a CAGR of 11.8% during (2022 - 2028). Additionally, The India market would experience a CAGR of 13.2% during (2022 - 2028).
Based on Type, the market is segmented into Superficial Peritoneal Lesion, Endometriomas, and Others. Based on Treatment, the market is segmented into Oral Contraceptives, Gonadotropin-releasing hormone (GnRH) medicines, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, Abbott Laboratories, and Consilient Health Limited.
Treatments exist that can lessen the disease's progression and improve symptoms. Treatments include painkillers like hormone supplements, ibuprofen, and paracetamol, and contraceptives, surgery to remove endometriosis tissue patches by cutting them out or by lasering (vaporizing) them, and an operation to remove all or some of the damaged organs.
The inability to conceive is one of the main effects of endometriosis. The patient might never be able to become pregnant (infertility). Having endometriosis surgically removed can increase a woman's chances of becoming pregnant. However, there is no assurance that they will be able to conceive after treatment. Endometriosis surgery could result in further complications. For instance, organ damage, hemorrhage, or infections. If surgery is advised, discuss the potential risks with the surgeon.
Due to a lack of menstrual awareness, restricted access to sanitary products, and a hostile school environment, girls may find it challenging to attend class. India's government and non-governmental organizations have created programs to minimize the difficulty of schoolgirls' menstruation (NGOs). This sought to identify barriers to menstruation management in schools and facilitators in three Indian states. The Indian government has established several programs to improve menstrual hygiene management (MHM) in schools, with assistance from a number of organizations, with the goal of enhancing knowledge about feminine hygiene and related diseases. It also plays a significant role in raising awareness among women regarding menstrual hygiene, well-being, and educational achievements. Women in this region experience a variety of menstrual issues, which inspires them to use femtech apps for efficient care. This will spur market expansion in the Asia Pacific region.
The China market dominated the Asia Pacific Endometriosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $177.3 million by 2028. The Japan market is estimated to grow a CAGR of 11.8% during (2022 - 2028). Additionally, The India market would experience a CAGR of 13.2% during (2022 - 2028).
Based on Type, the market is segmented into Superficial Peritoneal Lesion, Endometriomas, and Others. Based on Treatment, the market is segmented into Oral Contraceptives, Gonadotropin-releasing hormone (GnRH) medicines, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, Abbott Laboratories, and Consilient Health Limited.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Superficial Peritoneal Lesion
- Endometriomas
- Others
By Treatment
- Oral Contraceptives
- Gonadotropin-releasing hormone (GnRH) medicines
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Teva Pharmaceuticals Industries Ltd
- Sun Pharmaceutical Industries Ltd
- Sanofi S.A
- AbbVie, Inc
- AstraZeneca PLC
- Pfizer, Inc
- Merck & Co., Inc
- GlaxoSmithKline PLC
- Abbott Laboratories
- Consilient Health Limited
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Endometriosis Market, by Type
1.4.2 Asia Pacific Endometriosis Market, by Treatment
1.4.3 Asia Pacific Endometriosis Market, by Distribution Channel
1.4.4 Asia Pacific Endometriosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Endometriosis Market by Type
3.1 Asia Pacific Superficial Peritoneal Lesion Market by Country
3.2 Asia Pacific Endometriomas Market by Country
3.3 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Endometriosis Market by Treatment
4.1 Asia Pacific Oral Contraceptives Market by Country
4.2 Asia Pacific Gonadotropin-releasing hormone (GnRH) medicines Market by Country
4.3 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Endometriosis Market by Distribution Channel
5.1 Asia Pacific Hospital Pharmacy Market by Country
5.2 Asia Pacific Retail Pharmacy Market by Country
5.3 Asia Pacific Online Pharmacy Market by Country
Chapter 6. Asia Pacific Endometriosis Market by Country
6.1 China Endometriosis Market
6.1.1 China Endometriosis Market by Type
6.1.2 China Endometriosis Market by Treatment
6.1.3 China Endometriosis Market by Distribution Channel
6.2 Japan Endometriosis Market
6.2.1 Japan Endometriosis Market by Type
6.2.2 Japan Endometriosis Market by Treatment
6.2.3 Japan Endometriosis Market by Distribution Channel
6.3 India Endometriosis Market
6.3.1 India Endometriosis Market by Type
6.3.2 India Endometriosis Market by Treatment
6.3.3 India Endometriosis Market by Distribution Channel
6.4 South Korea Endometriosis Market
6.4.1 South Korea Endometriosis Market by Type
6.4.2 South Korea Endometriosis Market by Treatment
6.4.3 South Korea Endometriosis Market by Distribution Channel
6.5 Singapore Endometriosis Market
6.5.1 Singapore Endometriosis Market by Type
6.5.2 Singapore Endometriosis Market by Treatment
6.5.3 Singapore Endometriosis Market by Distribution Channel
6.6 Malaysia Endometriosis Market
6.6.1 Malaysia Endometriosis Market by Type
6.6.2 Malaysia Endometriosis Market by Treatment
6.6.3 Malaysia Endometriosis Market by Distribution Channel
6.7 Rest of Asia Pacific Endometriosis Market
6.7.1 Rest of Asia Pacific Endometriosis Market by Type
6.7.2 Rest of Asia Pacific Endometriosis Market by Treatment
6.7.3 Rest of Asia Pacific Endometriosis Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.3 Sun Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.4 Sanofi S.A.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.5 AbbVie, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Trials and Approvals:
7.6 AstraZeneca PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.7.5.2 Trials and Approvals:
7.8 Merck & Co., Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
7.8.5.1 Trials and Approvals:
7.9 GlaxoSmithKline PLC
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Trials and Approvals:
7.9.5.2 Acquisition and Mergers:
7.10. Consilient Health Limited
7.10.1 Company Overview
Companies Mentioned
- Teva Pharmaceuticals Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Sanofi S.A.
- AbbVie, Inc.
- AstraZeneca PLC
- Pfizer, Inc.
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- Abbott Laboratories
- Consilient Health Limited
Methodology
LOADING...
